Shares of Silk Road Medical SILK were flat in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share decreased 19.23% over the past year to ($0.31), which missed the estimate of ($0.28).
Revenue of $20,067,000 up by 17.86% year over year, which beat the estimate of $19,590,000.
Guidance
Silk Road Medical hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Nov 10, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/5vjzk4nx
Price Action
Company's 52-week high was at $75.80
Company's 52-week low was at $20.84
Price action over last quarter: Up 39.22%
Company Profile
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. Its approach for the treatment of carotid artery disease is called as transcarotid artery revascularization, or TCAR. The TCAR relies on two concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
